Articles
Articles
495 articles
J&J pausing a Phase 2 anti-tau trial with AC Immune should be read as a safety learning checkpoint, not a target verdict, and it forces a stricter mechanistic proof standard.
A versioned checklist and verification workflow to repair Copilot-related AI transparency disclosures when vendor terms change training-data use.
With $37M in QC3 selections, ARPA-E is redefining what “success” means for quantum chemistry: fewer abstract benchmarks, more validation tied to energy-relevant materials.
A LuxEM court’s willingness to reassess an administrative fine signals a shift: privacy compliance must produce regulator-grade penalty reasoning evidence, not just GDPR checkbox proof.
Interoperability in smart cities must survive vendor churn. This editorial shows how to specify portable data formats, audit trails, and edge-cloud governance as enforceable procurement terms.
NEPRA’s move from net metering to net billing changes the value of exported electricity, reshaping household payback, installer pipelines, and DISCO grid planning.
Microglial biology is now central to Alzheimer’s drug design. The next test is not elegance in mice, but biomarker-grade proof that TREM2-PLCG2 signaling can translate safely in humans.
Elegant Alzheimer’s biology is no longer enough. In 2026, biomarker strategy, patient selection, and auditable trial design decide which programs survive translation.
ALPR deployments often outsource data handling without making retention, oversight, and audit trails legible in procurement language.
The latest intelligence on emerging risks, delivered weekly.